Neervannan Seshadri 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 7, 2025
Insider Transaction Report
Form 4
Neervannan Seshadri
Chief Operating Officer
Transactions
- Award
Restricted Stock Units
2025-03-05+20,089→ 20,089 total→ Common Stock (20,089 underlying) - Award
Stock Option (right to buy)
2025-03-05+30,628→ 30,628 totalExercise: $44.54Exp: 2035-03-04→ Common Stock (30,628 underlying)
Footnotes (3)
- [F1]25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F3]The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.